All In Biotech

Drug Trial Radar · NCT01767311

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 856 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

856

Actual

Start

Dec 20, 2012

Primary completion

Dec 10, 2024

Study completion Dec 10, 2024

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Biogen
First posted
Jan 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy and to explore the dose response of lecanemab using a composite clinical score (ADCOMS). BAN2401-G000-201 Core study is an 18-month study in which 3 dose levels (2.5, 5, and 10 mg/kg) are given biweekly (once every 2 weeks) to separate groups of participants and 2 dose levels (5 and 10 mg/kg) are given monthly (once every 4 weeks) to separate groups of participants. Participants will be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Frequent interim analyses will be conducted to continually update randomization allocation on the basis of the primary clinical endpoint. Any participant who completes the study treatment (Visit 42 \[Week 79\] of the Core study) or discontinues the Core Study will be eligible to participate in the Extension Phase, provided they meet the Extension Phase inclusion and exclusion criteria. Participants will receive 10 mg/kg biweekly for up to 60 months or until the drug is commercially available in the country, where the subject resides, or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first. The Follow-up Visit in the Extension Phase will take place 3 months after the last dose of study drug.

Conditions

  • Alzheimer's Disease

Interventions

  • Lecanemab 2.5 mg/kgDrug

    2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion

  • Lecanemab 5.0 mg/kgDrug

    5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion

  • Lecanemab 10 mg/kgDrug

    10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.

  • Lecanemab 5.0 mg/kgDrug

    5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401

  • Lecanemab 10 mg/kgDrug

    10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401

  • PlaceboDrug

    biweekly (once every 2 weeks) administered as i.v. infusion

  • Lecanemab 10 mg/kgDrug

    10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12Time frame: Core Study Phase: at Month 12
  2. Core Study Phase: Number of Participants With All Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose of the study drug (Week 1) up to 90 days after last dose of study drug (up to 21 months)
  3. OLE Phase: Number of Participants With All TEAEs and SAEsTime frame: From first dose of the study drug (Week 1) up to 30 days after last dose of study drug (up to 61 months)

Locations

169 sites in 11 countries. Site status is shown where the registry gives one.

  • Facility #1

    Birmingham, Alabama

  • Facility #1

    Phoenix, Arizona

  • Facility #1

    Tucson, Arizona

  • Facility #1

    Carson, California

  • Facility #1

    Lomita, California

  • Facility #1

    Long Beach, California

  • Facility #1

    Los Alamitos, California

  • Facility #1

    Los Angeles, California

  • Facility #2

    Los Angeles, California

  • Facility #3

    Los Angeles, California

  • Facility #1

    Orange, California

  • Facility #1

    Oxnard, California

  • Facility #1

    San Diego, California

  • Facility #1

    Denver, Colorado

  • Facility #1

    New Haven, Connecticut

  • Facility #2

    New Haven, Connecticut

  • Facility #1

    Atlantis, Florida

  • Facility #1

    Boca Raton, Florida

  • Facility #2

    Boca Raton, Florida

  • Facility #1

    Bradenton, Florida

  • Facility #1

    Deerfield Beach, Florida

  • Facility #1

    Delray Beach, Florida

  • Facility #1

    Fort Myers, Florida

  • Facility #1

    Hallandale, Florida

  • Facility #1

    Hialeah, Florida

  • Facility #1

    Lake Worth, Florida

  • Facility #1

    Leesburg, Florida

  • Facility #2

    Leesburg, Florida

  • Facility #1

    Miami, Florida

  • Facility #2

    Miami, Florida

  • Facility #3

    Miami, Florida

  • Facility #1

    Miami Springs, Florida

  • Facility #1

    Naples, Florida

  • Facility #1

    Ocala, Florida

  • Facility #1

    Orlando, Florida

  • Facility #1

    Palm Beach Gardens, Florida

  • Facility #1

    St. Petersburg, Florida

  • Facility #1

    Sunrise, Florida

  • Facility #3

    Tampa, Florida

  • Facility #1

    Tampa, Florida

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.